Lp(a): a New Pathway to Target? Nick S. NurmohamedJordan M. KraaijenhofErik S. G. Stroes Nonstatin Drugs (L. Tokgozoglu and A.L. Catapano, Section Editors) Open access 06 September 2022 Pages: 831 - 838
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms Carl E. OrringerJelani K. GrantLale Tokgozoglu Nonstatin Drugs (L. Tokgozoglu and A.L. Catapano, Section Editors) 24 August 2022 Pages: 839 - 847
Ultra-processed Foods and Cardiometabolic Health Outcomes: from Evidence to Practice Filippa JuulAndrea L. DeierleinNiyati Parekh Nutrition (K. Petersen, Section Editor) 07 September 2022 Pages: 849 - 860
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease Ishaan JindalXiao Wang Genetics and Genomics (R.A. Hegele and L. Brunham, Section Editors) 22 August 2022 Pages: 861 - 866
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? Maurício Reis PedrosaDenise Reis FrancoFreddy Goldberg Eliaschewitz Cardiometabolic Disease and Treatment (R. Santos, Section Editor) 31 August 2022 Pages: 867 - 884
Best Practices for Designing Informative Trials Including Women Johny NicolasMadison EdensRoxana Mehran Women and Ischemic Heart Disease (J.M. Peña and F. Lin, Section Editors) 26 August 2022 Pages: 885 - 888